A-HEFT Trial Summary: Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure

a heft trial

2004 -0.1 3.1 A-HEFT TRIAL Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure Inclusion criteria: patients self-identified as 1,050 black (of African descent) with NYHA class III-IV patients HF ≥3 months on standard therapy, including ACEI/ARBs, ẞ-blockers, spironolactone, diuretics 6.2 double-blinded, parallel-group, randomized, placebo-controlled Objective: Among self-identified black patients with HFREF, does the combination of isosorbide dinitrate and hydralazine improve survival compared to placebo? ISDN/ hydralazine (n=518) VS PRIMARY OUTCOME Primary composite score (calculated from all-cause mortality, HF hospitalizations, and quality of life P=0.01 SECONDARY OUTCOME Adverse event: Severe HF exacerbation P=0.005 Placebo (n=532) All-cause mortality % RR 0.61; P=0.02 Anne L. Taylor, et al. N Engl J Med 2004; 351:2049-2057 -0.5 7.0 10.2 Conclusion: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.

Comments are closed.